logo
  

GEO Issues Q2 Outlook; Lifts FY21 AFFO View, Cuts Revenue Forecast - Quick Facts

While reporting higher profit and weak revenues in its first quarter, GEO Group, Inc. (GEO), a real estate investment trust, issued financial outlook for the second quarter and updated fiscal year 2021 forecast.

For the second quarter 2021, the company expects attributable net income in a range of $35 million to $38 million, adjusted funds from operations or AFFO in a range of $0.57 to $0.59 per share, and revenues in a range of $558 million to $563 million.

On average, analysts polled by Thomson Reuters expect earnings of $0.22 per share on revenues of $570.8 million. Analysts' estimates typically exclude special items.

Further, for the full year 2021, the company now expects attributable net income in a range of $141 million to $150 million, adjusted net income per share to be in a range of $1.02 to $1.10, AFFO in a range of $2.23 to $2.31 per share, and revenues in a range of $2.23 billion to $2.25 billion.

For the full year 2021, GEO previously expected attributable net income in a range of $0.88 to $0.98 per share, AFFO in a range of $1.98 to $2.08 per share, and revenues in a range of about $2.24 billion to $2.27 billion.

The Street expects the company to report earnings of $0.92 per share for the year on revenues of $2.27 billion.

The company said the updated guidance continues to assume a slow recovery from the COVID-19 pandemic throughout 2021.

In pre-market activity on NYSE, GEO shares were gaining 2.4 percent to trade at $5.88.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,... CVS Health said it has installed time delay safe technology in all 392 Illinois CVS Pharmacy locations, including those in Target stores, to help reduce organized retail crime. The installation of new safes for controlled substances are anticipated to help prevent pharmacy robberies. There is also potential for associated diversion of controlled substance medications, including opioid medications.
Follow RTT